Puma Biotechnology price to sales ratio PBYI

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 2.5×
8-year median: 1.1×
Against its 8-year history: 90th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.4× to 12.5×
Peer median: 1.5×

Puma Biotechnology's price to sales ratio is 2.5× as of Oct 23, 2026.

That is above its 8-year median of 1.1×, higher than on 90% of days in the last 8 years.

Over that time it ranged from 0.4× in Feb 2022 to 12.5× in Sep 2018.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.5×	1.3×	2.5×
2025	1.5×	0.6×	1.5×
2024	0.6×	0.5×	1.5×
2023	0.9×	0.5×	1.0×
2022	0.9×	0.4×	1.0×
2021	0.5×	0.5×	2.1×
2020	1.7×	1.0×	2.2×
2019	1.2×	0.9×	7.4×
2018	4.0×	3.8×	12.5×

Against its peers

Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.

Company	Price to sales ratio
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
ARVNArvinas	1.5×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
PCRXPacira BioSciences	1.9×
ANABAnaptysbio	n/m
Peer median	1.5×

Where Puma Biotechnology ranks

#49of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Puma Biotechnology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.